Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary
Year: 2024
Type: article
Abstract: Plain Language SummaryWhat is this summary about?This article summarises the findings from the CLARIFY-MS study. Cladribine tablets are an oral medication for the treatment of relapsing multiple sclerosis (MS). The exact number of tablets and number of days depends on the person's body weight. In the CLARIFY-MS study, researchers investigated whether treatment with cladribine tablets improved the health-related quality of life of people with highly active relapsing MS over a 2-year period. Most of the participants(348/482, 72%) were previously treated with other MS diseasemodifying treatments(DMTs) before starting treatment with cladribine tablets in this study.What were the results?Treatment with cladribine tablets significantly improved the health-related quality of life of the participants over the 2-year study period. Similar level of improvement in health-related quality of life was seen in participants who had previously been treated with other MS DMTs and in those who had not. Safety findings were also similar to previously reported data for cladribine tablets. No cases of the most severe grade of reduction in lymphocyte counts (grade 4; severely compromised immune system) were recorded.What do the results mean?Treatment with cladribine tablets improves the health-related quality of life of people with highly active relapsing MS regardless of whether they received or did not receive DMTs for MS before cladribine tablets treatment.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Institutions: Université de Bordeaux, Inserm, Neurocentre Magendie, Fondazione IRCCS Istituto Neurologico Carlo Besta, John Hunter Hospital, University of Newcastle Australia, Karolinska Institutet, Royal Holloway University of London, Maastricht University Medical Centre, Maastricht University, Zuyderland Medisch Centrum, University of Warmia and Mazury in Olsztyn, University of Catania, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco", Hospital Arnau de Vilanova, Merck Healthcare KGaA, Darmstadt (Germany), Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya, Charles University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4405417375